Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review
Current Oncology · 2025
DOI: 10.3390/curroncol32040191 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Oncology, 2025. Verfasst von Pratyusha Vadagam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, 800 Ridgeview Dr, Horsham, PA 19044, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson, Johnson & Johnson.
Abstract (Originalsprache)
Treatment resistance due to gene alterations remains a challenge for patients with EGFR-mutated advanced or metastatic non-small-cell lung cancer (a/mNSCLC). A systematic literature review (SLR) was conducted to describe resistance mutation profiles and their impact on clinical outcomes in adults with a/mNSCLC in the United States (US). A comprehensive search of MEDLINE and Embase (2018–August 2022) identified 2986 records. Among 45 included studies, osimertinib was the most commonly reported treatment (osimertinib alone: 15 studies; as one of the treatment options: 18 studies), followed by other tyrosine kinase inhibitors (TKIs; 5 studies) and non-TKIs (1 study). For first-line (1L) and second-line (2L) osimertinib, the most frequent EGFR-dependent resistance mechanisms were T790M loss (1L: 15.4%; 2L: 20.5–49%) and C797X mutation (1L: 2.9–12.5%; 2L: 1.4–22%). EGFR-independent mechanisms included MET amplification (1L: 0.6–66%; 2L: 7.2–19%), TP53 mutation (1L: 29.2–33.3%), and CCNE1 amplification (1L: 7.9%; 2L: 10.3%). For patients receiving osimertinib, EGFR T790M mutation loss, EGFR/MET/HER2 amplification, RET fusion, and PIK3CA mutation were associated with worse progression-free survival. Resistance mechanisms resulting from current NSCLC treatments in the US are complex, underscoring the need to address such heterogeneous resistance profiles and improve outcomes for patients with EGFR-mutated a/mNSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johnson & Johnson, 800 Ridgeview Dr, Horsham, PA 19044, USA.
- IQVIA Inc., 1850 Gateway Drive, San Mateo, CA 94404, USA.
ORCID-Profile: Pratyusha Vadagam
Förderung
- Johnson & Johnson
- Johnson & Johnson
Zitieren
APA
Vadagam, P., Waters, D., Bhagat, A., Kuang, Y., Uyei, J., & Vanderpoel, J. (2025). Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review. Current Oncology. https://doi.org/10.3390/curroncol32040191
Vancouver
Vadagam P, Waters D, Bhagat A, Kuang Y, Uyei J, Vanderpoel J. Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review. Current Oncology. 2025. doi:10.3390/curroncol32040191
BibTeX
@article{Vadagam2025,
author = {Vadagam, Pratyusha and Waters, Dexter and Bhagat, Anil and Kuang, Yuting and Uyei, Jennifer and Vanderpoel, Julie},
title = {Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32040191}
}
EUVIMED